TIVC Form 4: Christina Rizopoulos receives 7,500 stock options

Rhea-AI Filing Summary

Christina Rizopoulos, a director of Tivic Health Systems, Inc. (TIVC), was granted a stock option to purchase 7,500 shares of common stock with an exercise price of $3.32 per share, recorded with a transaction date of 08/06/2025. The filing shows 7,500 derivative securities beneficially owned following the grant.

The option vests in a series of four successive equal quarterly installments, rounded downward to the nearest whole share, such that the award is 100% vested upon the first anniversary of the grant date, and the option carries an expiration date of 08/05/2035. The grant ties director compensation to future share performance while establishing a roughly ten-year exercise window.

Insights

Corporate Governance Expert

TL;DR: Director awarded 7,500 options with quarterly vesting to align incentives; disclosure is routine and non-controversial.

The Form 4 documents a standard equity award to a board member rather than a cash payment or change in board composition. The grant details—7,500 options at a $3.32 exercise price, four equal quarterly vesting installments and full vesting at one year—indicate a retention and incentive structure. From a governance perspective, this is a commonplace mechanism to align long-term director interests with shareholders. The filing does not disclose broader plan limits or total dilution, so overall governance impact is limited to this isolated award.

Securities Analyst

TL;DR: Option grant gives director upside exposure; transaction size and financial impact are not determinable from this filing alone.

This Form 4 reports a derivative grant that creates potential future equity issuance if exercised. Key quantifiable elements are 7,500 options, $3.32 exercise price, vesting over four quarterly installments with full vesting at one year, and an expiration of 08/05/2035. The document does not provide company-wide share counts, plan reserve information, or immediate cash flow effects, so the materiality for shareholders cannot be assessed from this filing alone. As reported, the item is informational and routine rather than materially market-moving.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Valauri Christina Rizopoulos

(Last) (First) (Middle)

47685 LAKEVIEW BOULEVARD

(Street)

FREMONT CA 94538

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Tivic Health Systems, Inc. [ TIVC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
08/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Purchase)	$3.32	08/06/2025		A		7,500		(1)	08/05/2035	Common Stock	7,500	$0.00	7,500	D

Explanation of Responses:

1. The stock option vests in a series of four (4) successive equal quarterly installments, rounded downward to the nearest whole share, measured from the grant date, such that 100% of the stock option will be vested upon the first anniversary of the grant date.

	/s/ Jennifer Ernst, attorney-in-fact	08/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction was reported on the TIVC Form 4?

The Form 4 reports a grant of 7,500 stock options to director Christina Rizopoulos with a transaction date of 08/06/2025.

What is the exercise price for the options reported for TIVC?

The options have an exercise (conversion) price of $3.32 per share.

How do the granted TIVC options vest?

The options vest in a series of four successive equal quarterly installments, rounded downward to the nearest whole share, with 100% vesting upon the first anniversary of the grant date.

When do the TIVC options expire?

The filing lists an expiration date of 08/05/2035 for the reported option award.

How many derivative securities does the reporting person beneficially own after the transaction?

The Form indicates the reporting person beneficially owns 7,500 derivative securities following the reported transaction.